Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
- Author:
Hyo Song KIM
1
;
Chung Mo NAM
;
Suk Yong JANG
;
Sun Kyu CHOI
;
Minkyung HAN
;
Seonmin KIM
;
Maria Victoria MONETA
;
Sae Young LEE
;
Jae Min CHO
;
Diego NOVICK
;
Sun Young RHA
Author Information
- Publication Type:Original Article
- Keywords: Epidemiology; Korean population; Advanced soft tissue sarcoma; Treatment pattern; Modality
- MeSH: Adult; Cohort Studies; Diagnosis; Drug Therapy; Epidemiology; Humans; Incidence; Korea; National Health Programs; Sarcoma; Survival Rate
- From:Cancer Research and Treatment 2019;51(4):1380-1391
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status. MATERIALS AND METHODS: The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases. RESULTS: A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 person-years for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis. CONCLUSION: This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.
